BEACON-IPF – A Phase 2 Clinical Trial
May 15 @ 2:00 pm – 3:00 pm EDT
BEACON-IPF is a randomized, double-blind, dose-ranging, placebo-controlled study to evaluate the efficacy and safety of bexotegrast (PLN-74809) for the treatment of idiopathic pulmonary fibrosis (IPF).
Dr. Gregory P. Cosgrove, Medical Chief Officer at the Pulmonary Fibrosis Foundation and Vice President of Clinical Development at Pliant Therapeutics, will tell us more about this clinical trial on May 15!